In a report released today, Jeff Jones from Oppenheimer maintained a Hold rating on Chemomab Therapeutics (CMMB – Research Report). The company’s shares opened today at $0.60.
According to TipRanks, Jones is a 2-star analyst with an average return of -1.1% and a 32.79% success rate. Jones covers the Healthcare sector, focusing on stocks such as Ventyx Biosciences, Corvus Pharmaceuticals, and Pliant Therapeutics.
Chemomab Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $7.00.
See today’s best-performing stocks on TipRanks >>
Based on Chemomab Therapeutics’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $8.75 million. In comparison, last year the company had a GAAP net loss of $5.1 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Chemomab Therapeutics (CMMB) Company Description:
Anchiano Therapeutics Ltd. is a clinical-stage biopharmaceutical company, which engages in tin the discovery, development and commercialization of drugs for cancer-related diseases. Its products include two drugs for cancer BC-819 and BC-821. The company was founded by Avraham Hochberg in 2004 and is headquartered in Jerusalem, Israel.
Read More on CMMB:
